Metynor

Methylphenidate hydrochloride, the active ingredient in Metynor, is a central nervous system stimulant presented as an oral formulation for oral use. It treats attention deficit hyperactivity disorder and narcolepsy in children, adolescents, and adults.

GNH USA supplies Metynor as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metynor is a central nervous system stimulant indicated for specific neurobehavioral and sleep‑wake disorders.

Attention deficit hyperactivity disorder (children): improves attention, reduces hyperactivity and impulsivity. Attention deficit hyperactivity disorder (adults): enhances concentration and task completion. Narcolepsy: decreases excessive daytime sleepiness and cataplexy episodes.

Methylphenidate may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Insomnia or difficulty sleeping - Decreased appetite or weight loss - Headache - Stomach pain or nausea - Nervousness or anxiety - Increased heart rate

Serious or Rare Side Effects: - Cardiovascular events such as hypertension or arrhythmia - Psychotic symptoms including hallucinations or delusions - Severe allergic reactions (rash, swelling, difficulty breathing) - Priapism (prolonged erection) - Seizures - Marked mood swings or suicidal thoughts

Before initiating therapy, clinicians should evaluate several safety considerations.

Cardiovascular assessment: review patient history of heart disease, hypertension or arrhythmias. Psychiatric monitoring: observe for new or worsening anxiety, mania, or psychosis. Growth monitoring: regularly measure height and weight in pediatric patients. Drug abuse potential: prescribe only when benefits outweigh risk of dependence. Pregnancy and lactation: discuss potential risks with the prescriber before use. Store at ambient temperature: keep in original container, protect from moisture and heat.

Methylphenidate can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Antihypertensive agents: may cause excessive blood‑pressure reduction.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase methylphenidate plasma levels. - Antacids: can affect gastrointestinal absorption. - Alcohol: may potentiate central nervous system stimulation. - Other stimulants (e.g., amphetamines): additive cardiovascular and CNS effects.